{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "currency": "USD", "market": "us_market", "esgPopulated": false, "marketState": "PRE", "regularMarketChangePercent": 19.266047, "regularMarketPrice": 1.3, "exchange": "NMS", "shortName": "Aligos Therapeutics, Inc.", "longName": "Aligos Therapeutics, Inc.", "messageBoardId": "finmb_581475891", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "averageAnalystRating": "2.0 - Buy", "tradeable": false, "cryptoTradeable": false, "preMarketChange": -0.13999999, "preMarketChangePercent": -10.76923, "preMarketTime": 1684235321, "preMarketPrice": 1.16, "regularMarketChange": 0.20999992, "regularMarketTime": 1684180804, "regularMarketDayHigh": 1.34, "regularMarketDayRange": "1.15 - 1.34", "regularMarketDayLow": 1.15, "regularMarketVolume": 5472122, "regularMarketPreviousClose": 1.09, "bid": 0.0, "ask": 0.0, "bidSize": 40, "askSize": 8, "fullExchangeName": "NasdaqGS", "financialCurrency": "USD", "regularMarketOpen": 1.3, "averageDailyVolume3Month": 192573, "averageDailyVolume10Day": 658590, "fiftyTwoWeekLowChange": 0.45999998, "fiftyTwoWeekLowChangePercent": 0.54761904, "fiftyTwoWeekRange": "0.84 - 2.41", "fiftyTwoWeekHighChange": -1.1100001, "fiftyTwoWeekHighChangePercent": -0.46058095, "fiftyTwoWeekLow": 0.84, "fiftyTwoWeekHigh": 2.41, "firstTradeDateMilliseconds": 1602855000000, "priceHint": 4, "earningsTimestamp": 1683230702, "earningsTimestampStart": 1690973940, "earningsTimestampEnd": 1691409600, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -1.76, "epsForward": -1.15, "epsCurrentYear": -1.82, "priceEpsCurrentYear": -0.7142857, "sharesOutstanding": 39847800, "bookValue": 2.421, "fiftyDayAverage": 1.13916, "fiftyDayAverageChange": 0.16083992, "fiftyDayAverageChangePercent": 0.14119168, "twoHundredDayAverage": 1.24048, "twoHundredDayAverageChange": 0.059520006, "twoHundredDayAverageChangePercent": 0.047981434, "marketCap": 61455548, "forwardPE": -1.1304348, "priceToBook": 0.5369682, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-10-16", "displayName": "Aligos Therapeutics", "symbol": "ALGS"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "One Corporate Drive", "address2": "2nd Floor", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "(800) 466-6059", "website": "https://www.aligos.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-097558, which is in Phase I clinical trial for the treatment of coronavirus; and ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB). The company also develops ALG-055009, a small molecule THR-\u00df agonist that is in the Phase 2 clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). In addition, it develops siRNA drug candidate, ALG-125755, which is in Phase I clinical trial for the treatment of CHB. Aligos Therapeutics, Inc. has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 83, "companyOfficers": [{"maxAge": 1, "name": "Dr. Lawrence M. Blatt MBA, Ph.D.", "age": 60, "title": "CEO & Chairman", "yearBorn": 1962, "fiscalYear": 2022, "totalPay": {"raw": 832725, "fmt": "832.73k", "longFmt": "832,725"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Leonid  Beigelman Ph.D.", "age": 63, "title": "Pres & Director", "yearBorn": 1959, "fiscalYear": 2022, "totalPay": {"raw": 664433, "fmt": "664.43k", "longFmt": "664,433"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Julian A. Symons DPHIL", "age": 61, "title": "Exec. VP & Chief Scientific Officer", "yearBorn": 1961, "fiscalYear": 2022, "totalPay": {"raw": 618661, "fmt": "618.66k", "longFmt": "618,661"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Lesley Ann Calhoun CPA", "age": 56, "title": "Exec. VP & CFO", "yearBorn": 1966, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Lucinda Y. Quan J.D.", "age": 50, "title": "Exec. VP, Chief Bus. Officer & Gen. Counsel", "yearBorn": 1972, "fiscalYear": 2019, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Kristina  Engeseth", "title": "Exec. Director and Head of People & Culture", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Matthew W. McClure M.D.", "age": 50, "title": "Exec. VP & Chief Medical Officer", "yearBorn": 1972, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Sushmita M. Chanda DABT, Ph.D.", "age": 56, "title": "Exec. VP of Translational Safety Sciences", "yearBorn": 1966, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. David B. Smith Ph.D.", "title": "Exec. VP & Head of Chemical Operations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Tse-I  Lin Ph.D.", "title": "VP of Early Compound Devel. & Belgian Site Head", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 9, "boardRisk": 9, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}